# A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

> **NCT03416335** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** DSP-0509
- **DRUG:** DSP-0509, Pembrolizumab
- **DRUG:** DSP-0509, Pembrolizumab

## Key facts

- **NCT ID:** NCT03416335
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-01
- **Primary completion:** 2022-12-20
- **Final completion:** 2022-12-20
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Sponsor's decision to terminate the development of the program due to changing landscape.
- **Last updated:** 2024-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03416335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03416335, "A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03416335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*